Deuterated nitro benzothiazinones, nitro benzamides and related applications
Tech ID: 19-047
Inventor: Dr. Marvin Miller
Date Added: October 19, 2020
New nitro benzthiazinone anti-tuberculosis agents that reduce treatment duration and provide better efficacy
Tuberculosis (TB) is one of the top 10 causes of death, killing about 1.5 million people worldwide annually. Among the infected population, 5-10% develop active TB disease during their lifetime, resulting in 1 new active TB case every 3.5 seconds worldwide. Treatment of active TB requires the use of multi-drug therapy over 6-30 months and success is declining due to the emergence of drug-resistant strains of TB. Therefore, there is a need for new anti-TB drugs.
Researchers at the University of Notre Dame have developed a new group of anti-TB agents, a series of nitro benzothiazinone and nitrobenzamide compounds in which carbon hydrogen bonds have been replaced with isotopic carbon-deuterium bonds. The deuterated forms extend the half-life of the active component, increasing the efficacy of the drug, potentially decreasing the required dose and treatment duration.
- Longer half-life of the active component will reduce effective dosage
- Short treatment duration will potentially increase patient compliance
TB treatment market represents $916M (2016), growing at 5.2% annually
Technology Readiness Level
TRL 2 – Technology Concept and/or Application Formulated
Intellectual Property Status
PCT Application Filed